MELATONIN

Tardive Dyskinesia

Beijing HuiLongGuan HospitalSmall moleculeN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Tardive Dyskinesia cohort.

Asset / Sponsor	Phase	Rating
MT-5199 Neurocrine Biosciences	Phase 4	BBB
Ginkgo Biloba Beijing HuiLongGuan Hospital	Phase 3	BB
Varenicline Tartrate Corporal Michael J. Crescenz VA Medical Center	Phase 4	B
Safinamide Zambon SpA	Phase 3	B
Vitamin B6 Beersheva Mental Health Center	Phase 3	B

View all 14 →

Same molecule, other indications

MELATONIN is also rated in:

traumatic brain injuryDormant

BBB

Indicative ·

74 / 100

bipolar disorderDormant

BBB

Indicative ·

72 / 100

circadian rhythm sleep disorderDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.